Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Combined Fenobam and Amantadine Signigficantly Reduce Levodopa-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)-Lesioned Primate Model of Parkinson's Disease
Movement Disorders
(-)
016
Authors/Disclosures
Maurizio Facheris, MD, MSc (Vanqua Bio, Inc)
PRESENTER 		Dr. Facheris has received personal compensation for serving as an employee of Vanqua Bio. Dr. Facheris has or had stock in Vanqua Bio.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Thomas L. Winder, PhD, FACMG (Invitae Corp.) Dr. Winder has nothing to disclose.
No disclosure on file
No disclosure on file
Erwan Bezard, PhD (Basal Gang, CNRS UMR 5543) Dr. Bezard has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Treefrog Therapeutics. Dr. Bezard has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurobiology of Disease (Elsevier). Dr. Bezard has stock in Motac neuroscience. Dr. Bezard has stock in Treefrog Therapeutics. Dr. Bezard has stock in SE Therapeutics. The institution of Dr. Bezard has received research support from European Research Council. The institution of Dr. Bezard has received research support from Agence Nationale de la Recherche. The institution of Dr. Bezard has received research support from Michael J Fox Foundation. Dr. Bezard has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file